Immune surveillance of the CNS is critical for preventing infections; however, there is no accepted experimental model to assess the risk of infection when utilizing disease-modifying agents. We tested two approved agents for patients with multiple sclerosis (MS), glatiramer acetate and fingolimod, in an experimental model of CNS immune surveillance. C57BL/6 mice were infected with the ME49 strain of the neuroinvasive parasite Toxoplasma gondii (T. gondii) and then treated with GA and fingolimod. Neither treatment affected host survival; however, differences were observed in parasite load and in leukocyte numbers in the brains of infected animals. Here we demonstrate that this model could be a useful tool for analyzing immune surveillance.
Introduction
Currently there is no universally accepted experimental model to assess CNS immune surveillance. The lack of such a model is a substantial shortfall in drug development as it allows for the approval of pharmacological agents with unknown effects on CNS infections and neoplastic growth.
We recently developed and tested an experimental model of CNS immune surveillance using the protozoan Toxoplasma gondii (T. gondii). T. gondii is a highly prevalent obligate intracellular pathogen. Like other mouse strains, the C57BL/6 mouse strain is susceptible to the ME49 strain of T. gondii. Infection of C57BL/6 mice with T. gondii strain ME49 is characterized by a rapid expansion of tachyzoites in the host, which differentiate into bradyzoites and form tissue cysts predominantly in the CNS. The development of tissue cysts defines the chronic stage of the infection. Depletion of either CD4 + or CD8 + T-cell results in reactivation of the parasite, and is associated with rapid mortality of infected animals in this mouse strain (Gazzinelli et al., 1992) . The host survival of C57BL/6 mice following an infection with the ME49 strain of T. gondii is well established (Gazzinelli et al., 1992 (Gazzinelli et al., , 1991 Yarovinsky et al., 2006) .
We infected C57BL/6 mice with the ME49 strain of T. gondii and further treated with two pharmacological agents, glatiramer acetate (GA) and fingolimod. GA is approved for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) and in patients who experience an initial clinical relapse with MRI findings that are compatible with a diagnosis of MS. GA reduces the frequency of disease relapses (La Mantia et al., 2010) , and may decrease disease progression. The mechanism of action of GA is still not fully understood. However, immune responses under GA are shifted from a pro-inflammatory Th1 cytokine profile to an anti-inflammatory Th2 cytokine profile (Duda et al., 2000; Neuhaus et al., 2000) . GA also inhibits the activation and proliferation of encephalitogenic T cells, and the modulation of antigen presenting cells (Weber et al., 2004 (Weber et al., , 2007 . GA may also have neuroprotective properties through the induction of brain-derived neurotrophic factor (BDNF) by T cells and other cells within the CNS (Ziemssen et al., 2002; Aharoni et al., 2005) . Currently, GA is the only therapeutic intervention that does not require any laboratory testing while patients are being treated (Rommer et al., 2013) . Fingolimod is an agent with a relatively novel mode of action that is currently approved by the FDA to treat patients with RRMS (http://www.accessdata.fda.gov/ drugsatfda_docs/label/2010/022527s000lbl.pdf). In clinical studies fingolimod was efficient in reducing the rates of relapse and MRI evidence of inflammatory lesions (Brinkmann et al., 2010) . Fingolimod binds to sphingosine-1-phospate (S1P) receptors on the surface of leukocytes causing the receptors to be internalized thereby inhibiting Journal of Neuroimmunology 276 (2014) 232-235 
